Jelena Janjic - In vivo observation of intracellular oximetry in perfluorocarbon-labeled glioma cells and chemotherapeutic response in the CNS using fluorine-19 MRI.

Document created by Jelena Janjic on Aug 22, 2014
Version 1Show Document
  • View in full screen mode

  Publication Details (including relevant citation   information):

    Kadayakkara DK,   Janjic JM,   Pusateri LK,   Young WB,   Ahrens ET.

    Magn Reson Med. 2010 Sep 21. [Epub ahead of print]


  Preclinical development of therapeutic agents against cancer   could  greatly benefit from noninvasive markers of tumor   killing. Potentially,  the intracellular partial pressure of   oxygen (pO(2)) can be used as an  early marker of antitumor   efficacy. Here, the feasibility of measuring  intracellular   pO(2) of central nervous system glioma cells in vivo using    (19)F magnetic resonance techniques is examined. Rat 9L glioma   cells  were labeled with perfluoro-15-crown-5-ether ex vivo   and then implanted  into the rat striatum. (19)F MRI was   used to visualize tumor location in  vivo. The mean (19)F   T(1) of the implanted cells was measured using  localized,   single-voxel spectroscopy. The intracellular pO(2) in tumor    cells was determined from an in vitro calibration curve. The   basal pO(2)  of 9L cells (day 3) was determined to be 45.3 ±   5 mmHg (n = 6). Rats  were then treated with a 1× LD10 dose   of bischloroethylnitrosourea  intravenously and changes in   intracellular pO(2) were monitored. The  pO(2) increased   significantly (P = 0.042, paired T-test) to 141.8 ± 3  mmHg   within 18 h after bischloroethylnitrosourea treatment (day 4)   and  remained elevated (165 ± 24 mmHg) for at least 72 h   (day 6).  Intracellular localization of the   perfluoro-15-crown-5-ether emulsion in  9L cells before and   after bischloroethylnitrosourea treatment was  confirmed by   histological examination and fluorescence microscopy.    Overall, noninvasive (19)F magnetic resonance techniques may   provide a  valuable preclinical tool for monitoring   therapeutic response against  central nervous system or   other deep-seated tumors. Magn Reson Med,  2010. © 2010   Wiley-Liss, Inc.

  Address (URL):